Evidence map›Paper›PMID 40387570›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Novel Cyano-Artemisinin Dimer ZQJ29 Targets PARP1 to Induce Ferroptosis in Pancreatic Cancer Treatment.

Jianping Chen, Lingyun Yue, Yanna Pan, Bingying Jiang, Junfeng Wan, Haixia Lin, Fujiang Guo, Huiyu Li, Yajuan Li, Qingjie Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jianping ChenState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center for TCM Chemical Biology, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Lingyun YueState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center for TCM Chemical Biology, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yanna PanState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center for TCM Chemical Biology, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Bingying JiangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center for TCM Chemical Biology, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Junfeng WanCollege of Mathematics and Physics, Shanghai University of Electric Power, Shanghai, 201306, China.
Haixia LinDepartment of Chemistry, College of Sciences, Shanghai University, Shanghai, 200444, China.
Fujiang GuoSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Huiyu LiCollege of Mathematics and Physics, Shanghai University of Electric Power, Shanghai, 201306, China.
Yajuan LiInstitute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Qingjie ZhaoState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center for TCM Chemical Biology, Innovation Research Institute of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.ORCID https://orcid.org/0000-0002-3368-1290

Funding

Shanghai University of Traditional Chinese Medicine A1-U24-205-020404
6 · The paper itself

Abstract

Pancreatic cancer remains one of the most lethal malignancies in the digestive system, with limited available drugs and a need for improved efficacy. This unmet clinical need highlights the urgency to discover novel, highly efficient small-molecule compounds. Herein, a novel cyano-containing artemisinin dimer derivative, ZQJ29, is synthesized through structural modifications of artemisinin. Biological evaluation demonstrated that ZQJ29 effectively inhibits the proliferation of pancreatic cancer cells both in vitro and in vivo. ZQJ29 selectively targets PARP1 and has distinct structural features comparable to established PARP1 inhibitors such as Olaparib. Notably, ZQJ29 is the first reported artemisinin derivative to inhibit PARP1. Furthermore, the inhibition of PARP1 by ZQJ29 enhances the expression of TP53 and inhibits the SLC7A11/GPX4 pathway. The work first demonstrates that targeting PARP1 can induce ferroptosis in pancreatic cancer. These findings not only identify promising artemisinin derivatives for the development of therapies targeting pancreatic cancer but also provide scientific evidence supporting therapeutic strategies aimed at inducing ferroptosis in pancreatic cancer. This research lays a robust foundation for subsequent preclinical studies.

Indexed as

ArtemisininsFerroptosisPancreatic NeoplasmsPoly (ADP-Ribose) Polymerase-1AnimalsCell Line, TumorCell ProliferationHumansMiceMice, NudePoly(ADP-ribose) Polymerase InhibitorsXenograft Model Antitumor AssaysArtemisininsPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase Inhibitorsanti‐pancreatic cancerferroptosisnovel artemisinin derivativesPARP1 inhibitor

Identifiers

PMID40387570
PMCPMC12362764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.